Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00531518 · ClinicalTrials.gov registry record · NA
Early Detection and Intervention for the Prevention of Psychosis
A NA study of Depression and Schizophrenia, sponsored by MaineHealth.
- Completed
- Registry status
- NA
- Development phase
- 292
- Enrollment target
- 6
- Study locations
NCT00531518: Completed NA study of Depression and Schizophrenia, sponsored by MaineHealth.
NCT00531518 is a NA study of Depression and Schizophrenia that has completed, run by MaineHealth. The registered enrollment target is 292 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (63% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00531518, a NA study of Depression and Schizophrenia, has completed, sponsored by MaineHealth.
- COMPLETED
- Registry status
- NA
- Development phase
- 292 participants
- Enrollment target
- 6
- Study locations
Study Summary
EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States. The hypothesis is that very early identification and intervention will be effective in delaying or preventing onset of psychosis and improving social and occupational functioning.
Primary Outcome
Psychotic symptoms were assessed and scored using the Structured Interview for the Prodromal Syndrome (SIPS) and the Scale of Prodromal Symptoms (SOPS). The SOPS provides a measure of four domains of symptoms, including positive, negative, disorganized and general symptoms. The Positive Symptom sub-scale score reported is the sum of all five symptom items in the Positive Symptom sub-scale. The Positive Symptom sub-scale assesses psychotic symptoms, each item on a scale of 0-6. The sum scale scor
Conditions Studied
Interventions
- DRUG aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine
- BEHAVIORAL Psychoeducational multifamily group treatment
- BEHAVIORAL Supported employment and education
Study Locations (6)
California
- University of California-Davis, Imaging Research Center - Sacramento
Maine
- Portland Identification and Early Referral Program - Portland
Michigan
- Washtenaw County - Ann Arbor
New Mexico
- University of New Mexico - Albuquerque
New York
- Zucker Hillside Hosptial - Glen Oaks
Oregon
- Mid-Valley Behavioral Care Network - Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2007-10 |
| Est. Completion | 2013-09 |
| Phase | NA |
What the finished NCT00531518 record still lists
NCT00531518 is an interventional study that assigns participants to a tested intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (63% lower).
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine is the first listed.
NCT00531518 lists 6 locations in 6 states (California, Maine, Michigan).
Frequently Asked Questions
What is clinical trial NCT00531518 about?
NCT00531518 is a clinical study titled "Early Detection and Intervention for the Prevention of Psychosis". EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States. The hypothesis is that very early identification and intervention will be effective in delaying or preventing onse...
What is the current status of trial NCT00531518?
This trial is currently completed. It is a NA study. The enrollment target is 292 participants. The study started on 2007-10. Estimated completion is 2013-09.
What conditions does trial NCT00531518 study?
This clinical trial studies the following conditions: Depression, Schizophrenia, Bipolar Disorder, Psychotic Disorders.
What interventions are being tested in trial NCT00531518?
The interventions under investigation include: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine (DRUG), Psychoeducational multifamily group treatment (BEHAVIORAL), Supported employment and education (BEHAVIORAL).
Who is sponsoring clinical trial NCT00531518?
This trial is sponsored by MaineHealth, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00531518 being conducted?
This trial has 6 study locations across California, Maine, Michigan, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00531518's enrollment target sits among peer trials
292 153rd of 679 higher than 527 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia